Results 61 to 70 of about 22,609,350 (346)

Comparing the levels of CTLA‐4‐dependent biological defects in patients with LRBA deficiency and CTLA‐4 insufficiency

Allergy, 2022
AbstractBackgroundLipopolysaccharide‐responsive beige‐like anchor protein (LRBA) deficiency and cytotoxic T‐lymphocyte protein‐4 (CTLA‐4) insufficiency are recently described disorders that present with susceptibility to infections, autoimmunity, and lymphoproliferation.
Mehmet C. Catak, Bengu Akcam, Sevgi Bilgic Eltan, Royala Babayeva, Ibrahim S. Karakus, Gamze Akgun, Dilek Baser, Alper Bulutoglu, Feyza Bayram, Nurhan Kasap, Ayca Kiykim, Gonca Hancioglu, Sefika I. Kokcu Karadag, Yasemin kendir Demirkol, Selime Ozen, Sukru Cekic, Dilek Ozcan, Neslihan Edeer Karaca, Ayse S. Sasihuseyinoglu, Murat Cansever, Esra Ozek Yucel, Zeynep Tamay, Derya U. Altintas, Cigdem Aydogmus, Fatih Celmeli, Haluk Cokugras, Nesrin Gulez, Ferah Genel, Ayse Metin, Sukru N. Guner, Necil Kutukculer, Sevgi Keles, Ismail Reisli, Sara S. Kilic, Alisan Yildiran, Elif Karakoc‐Aydiner, Bernice Lo, Ahmet Ozen, Safa Baris   +38 more
openaire   +8 more sources

CTLA-4 Antibodies in Cancer Immunotherapy

, 2016
Activating human immune system to battle cancer has been a focus of cancer immunotherapy research from quite some time. After decades of disappointment, the tide has finally changed with some recent successes in clinical trials.
Veerendra Koppolu (3073263)
core   +1 more source

Effect of Cytotoxic T-Lymphocyte Antigen-4 on the Efficacy of the Fatty Acid-Binding Protein Vaccine Against Schistosoma japonicum

Frontiers in Immunology, 2019
The present study evaluated the impact of blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4) activity on the protective effect elicited by the fatty acid binding protein (FABP) vaccine against Schistosoma japonicum infection.
Chun-lian Tang, Qun Pan, Ya-ping Xie, Ying Xiong, Rong-hui Zhang, Jin Huang   +5 more
doaj   +1 more source

Polymorphic sites at the immunoregulatory CTLA-4 gene are associated with chronic chagas disease and its clinical manifestations. [PDF]

PLoS ONE, 2013
BACKGROUND:Chagas disease affects approximately 10 million people mainly in Latin America. The immune regulation by the host seems to be an essential factor for disease evolution, and immune system inhibitory molecules such as CTLA-4 and PD-1 favor the ...
Fabrício C Dias, Tiago da S Medina, Celso T Mendes-Junior, Roberto O Dantas, Cristina W Pissetti, Virmondes Rodrigues Junior, Renata Dellalibera-Joviliano, José A Marin-Neto, Fredy R S Gutierrez, Philippe Moreau, João S Silva, Eduardo A Donadi   +11 more
doaj   +1 more source

Anticorps anti-CTLA-4 [PDF]

médecine/sciences, 2011
L’immunotherapie par anticorps anti-CTLA-4, ipilimumab, est un traitement efficace du melanome metastatique utilise en monotherapie ou associe a la chimiotherapie (dacarbazine). L’effet therapeutique ne s’observe que chez 10 % a 20 % des patients, mais c’est la premiere fois qu’un medicament a un effet benefique sur la survie globale dans ce contexte ...
Caroline Robert, Christine Mateus
openaire   +1 more source

Functional Polymorphism of Ctla-4 and Icos Genes in Allogeneic Hematopoietic Stem Cell Transplantation

, 2011
T cells play a critical role in alloimmune recognition and thus contribute to graft-versus-host disease (GVHD) and relapse prevention in hematopoietic stem cell transplantation (HSCT). Cytotoxic T lymphocyte antigen-4 ( CTLA-4) and inducible costimulator
WU, JUI;TANG, JIH-LUH;WU, SHANG-JU;YANG, YA -CHIEN;YANG, YA-CHIEN, 吳睿;唐季祿;吳尚儒;楊雅倩   +1 more
core   +1 more source

DataSheet_1_Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer.docx

, 2023
IntroductionVirus vectored genetic vaccines (Vvgv) represent a promising approach for eliciting immune protection against infectious diseases and cancer.
Linda Nocchi (293755), Giuseppina Romano (15356689), Anna Morena D’Alise (15356680), Guido Leoni (823312), Irene Garzia (14946217), Emanuele Sasso (3934193), Luigia Infante (15356683), Elisa Scarselli (14895386), Fulvia Troise (11154339), Gabriella Cotugno (178089), Simona Allocca (15356686), Laura Seclì (14950612), Armin Lahm (139557), Alfredo Nicosia (182367)   +13 more
core   +1 more source

برهمکنش های مولکولی بین CTLA-4 و CD80/CD86 در تنظیم پاسخ های ایمنی: مقاله مروری [PDF]

Majallah-i Dānishkadah-i Pizishkī-i Dānishgāh-i ̒ Ulūm-i Pizishkī-i Mashhad.
یکی از اصلی ترین مکانیسم های تنظیم پاسخ های ایمنی برهم کنش متقابل CTLA-4 و CD80/CD86 است. CTLA-4 نوعی رسپتور مهاری و دارای لیگاندهای CD80/CD86 و مشترک با گیرنده کمک محرک CD28 است. CTLA-4 طی فرآیندی به نام ترانس ‌اندوسیتوزیس این لیگاندها را اندوسیتوز کرده
زهرا درویش خلیل آبادی, آمنه رئوف رحمتی, سید علیرضا اسماعیلی   +2 more
doaj   +1 more source

CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4

Frontiers in Immunology, 2020
CD80 and CD86 are expressed on antigen presenting cells and are required to engage their shared receptor, CD28, for the costimulation of CD4 T cells. It is unclear why two stimulatory ligands with overlapping roles have evolved.
Neil Halliday, Neil Halliday, Cayman Williams, Alan Kennedy, Erin Waters, Anne M. Pesenacker, Blagoje Soskic, Claudia Hinze, Tie Zheng Hou, Behzad Rowshanravan, Daniel Janman, Lucy S. K. Walker, David M. Sansom   +12 more
doaj   +1 more source

Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes

Biomedical Journal, 2021
Autoimmune lymphoproliferative syndrome (ALPS) is an inherited non-malignant and non-infectious lymphoproliferative syndrome caused by mutations in genes affecting the extrinsic apoptotic pathway (FAS, FASL, CASP10).
Laura Gámez-Díaz, Bodo Grimbacher
doaj   +1 more source